Xhale

Palmetto Pharmaceuticals(原eNOS Pharmaceuticals)開發了通過上調內皮型一氧化氮合酶(eNOS)來改善和恢複血液流動並降低甘油三酯的產品。該公司的首個候選藥物L-arginine緩釋治療高甘油三酯血症，目前正在德國進行臨床試驗。

Indena是一家致力於鑒定、開發和生產從植物中提取的活性成分的公司，用於製藥、保健食品和化妝品行業。Indena是一家意大利私營公司，擁有約700名員工，其中10%致力於全職研究，旨在管理全球40多個國家的種植、製造和分銷業務。Indena成功的關鍵在於其研究，包括:藥用植物的藥理效益篩選;確定新的有效原則;並開發了處於工業應用前沿的萃取淨化係統。植物化學研究在意大利塞塔拉的Indena自己的研究中心進行。Indena還與世界上最負盛名的大學和私人研究機構合作，進行安全性和有效性的生物評估，直至臨床i期。該研究的主要戰略目標之一是開發新的藥物應用活性原理。這裏也是保健品、化妝品行業不可或缺的基地。在製藥領域，Indena目前專注於抗癌治療的開發，繼紫杉醇成功之後，還專注於抗微生物和抗病毒藥物的開發。此外，還在研究治療中樞神經係統病理和功能障礙的積極原則，如抑鬱、焦慮、陽痿、睡眠障礙和痛覺障礙。 Today Indena is also concentrating its efforts on the industrial production of high-quality standardised active principles derived from plants, which are important ingredients in health food products. In fact, the company produces standardised extracts from edible plants that are traditionally recognised as having therapeutic properties, as well as from plants that have proven pharmacological value. Indena's research and production activities are particularly attentive to plant-based principles that have anti-oxidant properties and are effective in preventing damage caused by free radicals. Backed by over 80 years of botanical experience, the Italian company has developed a plantation network, managed by experts, to supply its research and production centers with officinal plants, while at the same time ensuring bio-diversity and protecting the ecosystem balance from uncontrolled harvesting. Today more than 60% of the raw material used in the manufacturing process comes from cultivation. Indena's decades-long global presence in the plant extraction industry is a guarantee of its in-depth knowledge and understanding of the business, market trends and legal considerations, through constant communication and interaction between the company's experts and the major international regulatory authorities such as WHO, EMEA, and ESCOP, and main pharmacopoeias.

Perpetual Pharmaceutical公司正在開發一種名為Briodurance的胰島素類藥物，這種藥物可以感知血糖水平的上升

OcuNexus Therapeutics是一家處於發展階段的生物製藥公司，開發治療眼前和眼後疾病和障礙的方法。

CSF Therapeutics正在開發一種腦血流裝置，以預防神經衰弱和死亡，僅在美國就有1000多萬人受到影響，包括中風和阿爾茨海默病等適應症。基於克利夫蘭診所的研究，CSF Therapeutics的設備旨在無限增加腦血流量，而不影響血管或係統功能。

PluroGen Therapeutics提供臨床先進和優勢的燒傷、傷口和皮膚護理產品。公司與醫生、護士、患者和醫療機構密切合作，為燒傷、傷口和皮膚護理提供最好的產品，幫助人們擁有更好的生活質量。公司的主要平台是其核心的PluroGel表麵活性劑技術，該技術為產品提供了範式轉變，卓越和差異化的核心功能，生物物理和性能功能，從而形成獨特和優勢的多功能產品。